Close
Use this page to view details for the decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Myelodysplastic Syndromes (MDS) (CAG-00415R).
Use this page to view details for the decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Myelodysplastic Syndromes (MDS) (CAG-00415R).
Acalabrutinib combination therapy elicits statistically significant improvement in progression-free survival for treatment-naive mantle cell lymphoma.
Darolutamide uptake in metastatic hormone-sensitive prostate cancer has become routine both in doublet and triplet regimens in community urology practices.
Despite improved survival rates and guideline recommendations, many eligible patients with metastatic Merkel cell carcinoma are not receiving immunotherapy.
TAR-210 was safe and showed promising clinical activity in patients with FGFR-altered high- and intermediate-risk non–muscle-invasive bladder cancer.
In this expert analysis of the AGAVE-201 trial data, the efficacy of a monoclonal antibody in treating graft versus host disease is discussed, with the…
Major Finding: A pan-cancer resource was developed that identifies the presence and relevance of the metastatic microbiome. Approach: Multi-omic analyses were conducted on 4,160 metastatic…
Amandeep Salhotra, MD, discusses the feasibility and safety of Orca-T graft in patients undergoing allogeneic transplant for hematologic malignancies.
As part of its Speaking Out video series, Targeted Oncology spoke with Howard D. Edington, MD, about the benefits of using oncolytic viruses in cancer…
Wolters Kluwer (“we” or “us”) wants to inform you about the ways we process your personal information. In this Privacy & Cookie Notice we explain…